Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), has announced that it has agreed to sell, by way of an underwritten offering, 12,250,000 shares of its common stock at a price of US$2.42 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 14,630,000 shares of common stock at a price of US$2.4199 per pre-funded warrant, for expected aggregate gross proceeds of approximately US$65 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the US$0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Terns.
Latham & Watkins LLP represents Terns Pharmaceuticals in the offering with a capital markets deal team led by Brian Cuneo and Erica Kassman, with AJ Blair. Advice was also provided on tax matters by Katharine Moir, with Gregory Conyers.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.